It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT - Free Report) . Shares have added about 24.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Sarepta Therapeutics due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Sarepta Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.
Wider-Than-Expected in Q4, Sales Beat EstimatesSarepta reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was attributed to an increase in operating expenses incurred during the quarter. In the year-ago period, the company posted an adjusted EPS of $1.91.
The adjusted figures exclude depreciation and amortization costs, stock-based compensation expenses, gains on strategic investments, losses on debt extinguishment and restructuring charges. Including these items, the loss during the quarter was $3.93 against an EPS of $1.50 in the year-ago period.
Sarepta recorded total revenues of $442.9 million, down nearly 33% year over year. This downtick was due to lower sales of Elevidys. The reported figure beat the Zacks Consensus Estimate of $408.5 million.
Quarter in DetailProduct revenues fell 42% year over year to $369.6 million.
The company recorded $259 million from the product sales of its three PMO therapies, up 2% year over year. The figure missed the Zacks Consensus Estimate of $270 million.
Sarepta generated $110 million from Elevidys sales, down more than 71% year over year, primarily due to its decision to suspend shipments to non-ambulatory patients in June 2025 amid safety concerns. The therapy’s sales missed the Zacks Consensus Estimate of $114 million.
SRPT recorded approximately $73.3 million in collaboration and other revenues, compared to $20.3 million in the year-ago period. This uptick was mainly due to higher contract manufacturing revenues, driven by higher volume of shipments of Elevidys to Roche.
Adjusted research and development (R&D) expenses totaled $308.1 million, up 78% year over year. This upside is primarily due to an increase in milestone expenses made toward pipeline development during the quarter.
Adjusted selling, general & administrative (SG&A) expenses declined 20% to $105.4 million, primarily due to the company’s restructuring plan launched in July 2025.
Full-Year 2025 ResultsSarepta reported total revenues of $2.2 billion, up 16% year over year.
The adjusted loss in 2025 stood at $5.05 per share against adjusted EPS of $3.71 in the year-ago period.
2026 GuidanceAt the conference call, management issued fresh guidance for net product revenue projection for full-year 2026. It expects figures between $1.2 billion and $1.4 billion. The company projects total collaboration, contract manufacturing and royalty revenues to be between $450 million and $550 million.
Sarepta reiterated its guidance for expenses. It expects the combined adjusted R&D and SG&A expenses to be in the $800-$900 million range.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted 9.79% due to these changes.
VGM ScoresAt this time, Sarepta Therapeutics has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Interestingly, Sarepta Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerSarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Prothena (PRTA - Free Report) , a stock from the same industry, has gained 10.2%. The company reported its results for the quarter ended December 2025 more than a month ago.
Prothena reported revenues of $0.02 million in the last reported quarter, representing a year-over-year change of -99.1%. EPS of -$0.44 for the same period compares with -$1.08 a year ago.
Prothena is expected to post a loss of $0.37 per share for the current quarter, representing a year-over-year change of +67%. Over the last 30 days, the Zacks Consensus Estimate has changed +4.1%.
Prothena has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates both opportunity and risk that investors need to understand clearly right now.
The fund carries over $8 billion in assets across 150+ holdings, with 96% of the portfolio in healthcare. XBI is up about 2% year to date, but that calm surface masks a rougher month: shares pulled back roughly 4% over the past 30 days. The one-year picture is far more compelling, with the fund up 46% over the past year. Zoom out five years, though, and the fund is still down about 6%, a reminder of how brutal the 2021-2022 rate-driven selloff was for biotech.
The FDA’s New Leadership Changes the Calculus for Every Holding The single biggest macro factor shaping XBI’s next 12 months is the FDA regulatory environment under its new leadership. Marty Makary was confirmed as FDA Administrator, resolving genuine uncertainty about who would run the agency. That clarity matters because biotech valuations are built almost entirely on the probability of regulatory approval, and an unpredictable FDA is a discount rate in itself.
The concern now is not who sits at the top but what is happening beneath. DOGE-related staffing reductions and broader HHS restructuring have raised questions about review capacity and advisory committee continuity. A slower approval pipeline would compress valuations across XBI’s 150+ holdings simultaneously, hitting small and mid-cap names hardest because they have no commercial revenue to cushion the blow.
Watch the FDA’s published PDUFA action dates and advisory committee calendars monthly. A pattern of delays or unexpected refusals would be the clearest warning sign. A steady approval cadence through mid-2026 would confirm that operational disruption has been contained.
Equal Weight Means Every Clinical Readout Hits the Whole Fund Because each holding starts at roughly the same portfolio weight, a single binary clinical event, whether a phase 3 success or failure, moves the fund in a way that a cap-weighted index would barely register.
Several holdings have high-stakes readouts coming. Moderna (NASDAQ:MRNA | MRNA Price Prediction), currently the fund’s largest position at about 2.3% weight, expects phase 3 norovirus and adjuvant melanoma data in 2026. Moderna is up about 82% year to date, driven partly by a patent settlement that sparked a sharp sentiment reversal on Reddit. A post on r/wallstreetbets titled “Moderna +10% after-hours as Moderna agrees to pay up to $2.25B to settle COVID vaccine patent dispute” captured the mood shift, accumulating 270 upvotes by March 5.
Krystal Biotech (NASDAQ:KRYS) is the fund’s quiet fundamental standout, posting 94% gross margins and $204 million in net income for full-year 2025, with VYJUVEK revenue growing 34% year over year. Phase 3 readouts in corneal DEB and neurotrophic keratitis are both expected before year-end.
Sarepta Therapeutics (NASDAQ:SRPT) is attempting a recovery after ELEVIDYS revenue fell 33% year over year in Q4 2025 following a safety-driven suspension of non-ambulatory shipments. Management expects to return to profitability in 2026, but the path depends on label rehabilitation and a Japan launch that began in February.
The quarterly rebalance is where this mechanic becomes most visible. XBI rebalances in March, June, September, and December, equalizing weights each time: strong performers get trimmed and beaten-down names get topped up. Watch the holdings file after each rebalance to see which names gained or lost weight, particularly whether high-burn, pre-revenue names like Recursion Pharmaceuticals (NASDAQ:RXRX), down 23% year to date amid dilution concerns from a $300 million ATM equity offering, are being added to or reduced from the portfolio.
If the FDA maintains consistent review timelines through mid-2026 and the June rebalance does not materially increase exposure to high-burn names with no near-term catalysts, XBI’s one-year momentum has a credible foundation. If either condition breaks, the equal-weight structure that amplified the upside will amplify the downside just as efficiently.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in the first quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 113,855 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each offering a differentiated mechanism, commercial traction, or platform technology that a deep-pocketed acquirer would find difficult to replicate organically.
Incyte Incyte (NASDAQ: INCY | INCY Price Prediction) tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
The stock trades at roughly 14x trailing earnings with an analyst consensus target of $107.14, suggesting meaningful acquisition premium headroom. CEO Bill Meury noted the company enters 2026 with “strong business momentum, an innovative, strategically focused pipeline, and a clear strategy for capital allocation and long-term growth.” The primary risk remains Jakafi patent exposure, but the breadth of the franchise mitigates single-asset concentration.
Alnylam Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ: ALNY) represents the most transformative platform play on this list. FY2025 revenue surged 65.2% YoY to $3.71 billion, with AMVUTTRA generating $826.6 million in Q4 2025 (+189% YoY) following its landmark ATTR-CM approval. The company achieved full-year GAAP profitability for the first time in 2025 with net income of $313.7 million. 2026 guidance calls for $4.9 billion to $5.3 billion in total net product revenues.
At a $43.9 billion market cap and trading down 16.8% YTD, Alnylam’s RNAi platform spanning cardiovascular, neurological, and rare disease indications would deliver unmatched therapeutic breadth to a strategic acquirer. The analyst consensus target is $449.32, implying substantial upside from current levels near $333 a share.
Kymera Therapeutics This company’s targeted protein degradation platform has attracted collaborations from both Sanofi and Gilead Sciences, validating its first-in-class approach. Kymera Therapeutics (NASDAQ: KYMR) stock has surged 204.3% over the past year, reflecting growing conviction in its STAT6 degrader program. Phase 1b data for KT-621 in atopic dermatitis showed results in line with or numerically exceeding dupilumab after four weeks.
The company holds approximately $1.62 billion in cash with runway into 2029 and recently initiated dosing in its KT-579 Phase 1 trial in February 2026, the first IRF5-directed mechanism in the clinic. The CDK2 molecular glue program with Gilead carries up to $750 million in total potential payments and is directly relevant to oncology acquirers. Analysts maintain a consensus target of $119.14, versus a current price near $83 per share.
Arcus Biosciences Arcus Biosciences (NASDAQ: RCUS) holds what management describes as a best-in-class HIF-2α inhibitor in casdatifan, with Phase 1 data showing a 45.2% confirmed ORR and 15.1-month median PFS at the Phase 3 dose in IO-experienced clear cell RCC. CEO Terry Rosen cited “an over $5 billion peak sales opportunity” across IO-experienced and first-line ccRCC settings.
With a $2.7 billion market cap and $1.01 billion in cash providing runway to at least H2 2028, Arcus offers an acquirer a clean balance sheet and multiple Phase 3 readouts ahead. The stock trades well below analyst consensus of $33.80 and is down 9.4% YTD, potentially creating an attractive entry point before PEAK-1 data materializes.
Sarepta Therapeutics The M&A appeal here is rooted in deep valuation compression. Sarepta Therapeutics (NASDAQ: SRPT) stock has fallen 65.9% over the past year, pushing its market cap to roughly $2.3 billion against FY2025 revenue of $2.20 billion. ELEVIDYS remains the only approved gene therapy for ambulatory DMD patients, and its Japan launch by Chugai in February 2026 is expected to trigger a $40 million milestone payment. The siRNA pipeline includes five clinical-stage RNAi programs targeting rare neurological diseases.
CEO Doug Ingram stated the company entered 2026 with “solid financial footing…durable approved therapies…exciting, potentially best-in-class siRNA pipeline.” Regulatory overhang on ELEVIDYS and a deep EPS miss of −$3.58 versus the −$1.05 consensus in Q4 2025 weigh on sentiment, but the price-to-sales ratio of 0.978x reflects a historically rare discount for a commercial-stage gene therapy franchise.
Conclusion Across these five names, several themes emerge: validated novel platforms (RNAi, TPD, gene therapy), oncology pipeline depth, and depressed valuations relative to clinical and commercial potential. The most immediate M&A candidates are Arcus and Sarepta, given their compressed market caps, while Incyte and Alnylam offer scale and revenue durability that would appeal to a larger strategic buyer. Kymera’s platform optionality across oncology and immunology makes it a longer-duration but high-conviction target. Key uncertainties include Phase 3 replication risk for casdatifan, regulatory resolution for ELEVIDYS, and the timing of KT-621 Phase 2b data, all of which could materially shift acquisition premiums in either direction.
Aberdeen Group plc increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,251,593 shares of the biotechnology company's stock after purchasing an additional 268,829 shares during the
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentation.
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarept.
Sarepta Therapeutics (SRPT - Free Report) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +253.07%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.71 per share when it actually produced a loss of $3.58, delivering a surprise of -404.23%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Sarepta Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $730.8 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 56.20%. This compares to year-ago revenues of $744.86 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Sarepta Therapeutics shares have added about 1.3% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for Sarepta Therapeutics?While Sarepta Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Sarepta Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $446.54 million in revenues for the coming quarter and $3.90 on $1.74 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Foghorn Therapeutics Inc. (FHTX - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026.
This company is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +6.7%. The consensus EPS estimate for the quarter has been revised 3.5% lower over the last 30 days to the current level.
Foghorn Therapeutics Inc.'s revenues are expected to be $9.24 million, up 55.2% from the year-ago quarter.
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Key Takeaways Sarepta posted Q1 EPS of $3.16 and revenues of $730.8M, topping consensus estimates.SRPT's Elevidys sales fell 73% after the suspension to non-ambulatory patients.Sarepta maintained 2026 product revenue guidance of $1.2B-$1.4B amid pipeline progress. Sarepta Therapeutics, Inc. (SRPT - Free Report) reported a first-quarter 2026 adjusted earnings per share (EPS) of $3.16, which beat the Zacks Consensus Estimate of 90 cents. In the year-ago quarter, the company posted a loss of $3.42 per share due to a one-time charge incurred to close the multi-billion-dollar collaboration deal with Arrowhead Pharmaceuticals .
The adjusted figures exclude depreciation and amortization costs, stock-based compensation expenses, gains on strategic investments and certain interest expense/income. Including these items, EPS during the quarter was $2.88 against a loss of $4.60 in the year-ago period.
Sarepta recorded total revenues of $730.8 million, down 2% year over year. This downtick was due to lower sales of Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). Yet, the figure beat the Zacks Consensus Estimate of about $468 million.
SRPT’s Stock PerformanceYear to date, Sarepta’s shares have gained 7% against the industry’s 2% decline.
Image Source: Zacks Investment Research
More on SRPT’s EarningsSarepta’s commercial portfolio includes three approved RNA-based PMO therapies — Exondys 51, Vyondys 53 and Amondys 45 — and Elevidys, all targeting DMD. Product revenues fell 46% year over year to $330.5 million.
The company recorded $228.6 million from the product sales of its three PMO therapies, down 3% year over year. The figure beat the Zacks Consensus Estimate of $227 million.
Sarepta generated $102 million from Elevidys sales, down 73% year over year, primarily due to its decision to suspend shipments to non-ambulatory patients in June 2025 amid safety concerns. The therapy’s sales also beat the Zacks Consensus Estimate of $97 million.
SRPT recorded $400.3 million in collaboration and other revenues, compared to $133.3 million in the year-ago period. This increase was primarily driven by higher collaboration revenues related to Roche’s (RHHBY - Free Report) declined option for certain program rights, milestone payments tied to the first commercial dosing of Elevidys in Japan and higher Elevidys supply shipments to Roche.
Sarepta and Roche entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, RHHBY has exclusive rights to launch and market Elevidys in ex-U.S. markets.
Discussion on SRPT’s Operating CostsAdjusted research and development (R&D) expenses totaled $137.5 million, down 82% year over year. This decline was primarily due to the recognition of $583.6 million in upfront and collaboration license fees paid to Arrowhead in the year-ago period.
Adjusted selling, general & administrative (SG&A) expenses declined 20% to $86.1 million, primarily due to the company’s restructuring plan launched last year in July.
SRPT Reiterates 2026 GuidanceSarepta expects net product guidance to be between $1.2 billion and $1.4 billion.
The company forecasts combined adjusted R&D and SG&A expenses in the $800-$900 million range.
Updates on SRPT’s Pipeline & Other NewsLast month, the company submitted regulatory filings to the FDA seeking to convert the accelerated approvals granted for Vyondys 53 and Amondys 45 into full/traditional approvals. These filings are supported by data from a late-stage confirmatory study and substantial real-world evidence.
In March, SRPT announced that screening and enrollment are underway in cohort 8 of the phase Ib ENDEAVOR study. This cohort is designed to improve the safety profile of Elevidys in non-ambulatory patients by combining it with an enhanced sirolimus-based immunosuppressive regimen. Data from this cohort will be used to determine whether administering sirolimus before or after Elevidys infusion can help reduce the risk of acute liver complications.
In March, Sarepta also reported promising early results from two ongoing phase I/II studies — one for SRP-1001 for facioscapulohumeral muscular dystrophy type I (FSHD1) and another for SRP-1003 for myotonic dystrophy type I (DM1). The data showed that both drugs, which were acquired from Arrowhead last year, achieved high muscle concentrations without dose-limiting toxicity in patients.
SRPT’s Zacks RankSarepta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET.
The presentations will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billions in cash while staring down looming patent cliffs.
That combination is creating a fertile backdrop for smaller biotech companies with strong pipelines, differentiated technology, and upcoming catalysts. Here are my top three biotech stocks for May.
Image source: Getty Images.
Schrödinger Schrödinger (SDGR 1.03%) develops physics-based software and artificial intelligence (AI) tools that pharmaceutical companies use to simulate how drug molecules behave before moving into expensive laboratory and human testing.
Major drugmakers use its platform to accelerate drug discovery in areas such as cancer, autoimmune diseases, and precision medicine. At the same time, the company also advances its own pipeline of internally developed drug candidates.
Worth noting: Schrödinger is one of the few AI-driven biotech companies that actually generates revenue, too. The company reported $256 million in total revenue for 2025, including $200 million in software revenue and annual contract value (ACV) of $198 million. Management is guiding for 10% to 15% ACV growth in 2026, with an expected range of $218 million to $228 million.
Today's Change
(
-1.03
%) $
-0.15
Current Price
$
14.45
The company's balance sheet also remains solid. Management has repeatedly emphasized that existing cash reserves support operations well into the company's path toward positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by the end of 2028.
What investors are really betting on, however, is the platform's ability to generate successful internal drug candidates. Schrödinger continues advancing oncology and precision medicine programs while maintaining partnerships with major pharmaceutical companies.
This is still a development-stage biotech story in many respects, but the software business gives the company a revenue foundation that most early stage biotech companies simply do not have. And that's not trivial.
Sarepta Therapeutics Sarepta Therapeutics (SRPT +0.93%) remains one of the most controversial stocks in biotech, but it also remains one of the few gene therapy companies generating substantial commercial revenue.
The company reported full-year 2025 net product revenue of $1.86 billion. Of that total, approximately $899 million came from Elevidys, Sarepta's one-time gene therapy designed to deliver a functional version of the dystrophin gene (a protein that helps keep muscle cells strong and stable during movement) to patients with Duchenne Muscular Dystrophy.
Another $966 million came from the company's PMO franchise, which includes a variety of drugs that help certain Duchenne patients produce shortened forms of the dystrophin protein.
Today's Change
(
0.93
%) $
0.14
Current Price
$
15.14
The problem is that safety concerns surrounding Elevidys continue to weigh heavily on investor sentiment. Multiple patient deaths tied to acute liver failure forced the company into shipment pauses, FDA scrutiny, and labeling changes over the past year.
Despite the controversy, Elevidys continues to generate significant commercial revenue. Sarepta treated more than 1,300 patients with Elevidys and maintained its 2026 revenue guidance of $1.2 billion to $1.4 billion.
The market is now trying to determine whether Sarepta can stabilize the safety narrative while continuing to expand its Duchenne Muscular Dystrophy franchise. This stock still carries significant risk. Ongoing regulatory scrutiny has weakened investor confidence, but unlike many biotech companies trading on future possibilities, Sarepta already has a large commercial business generating real cash flow. And a lot of it.
NRX Pharmaceuticals NRX Pharmaceuticals (NRXP 0.77%) remains highly speculative, but the company has begun to generate the kind of regulatory momentum that makes it attractive.
If you're unfamiliar, NRX is a small biotech company developing treatments for severe depression, suicidal bipolar disorder, and other serious central nervous system conditions. The company's lead drug candidate, NRX-101, is designed to help stabilize patients following ketamine treatment while potentially reducing relapse and suicidal risk.
Ketamine is a dissociative anesthetic used to rapidly treat severe depression and suicidal thoughts, particularly in patients who have not responded to traditional antidepressants.
The biggest recent development came in March, when the FDA informed the company it had not identified any major problems with how NRX's preservative-free ketamine performed compared to an already approved version of ketamine. The company now expects a potential FDA decision this summer.
More recently, NRX announced FDA clearance to proceed with a clinical trial combining NRX-101 with robotic-enabled transcranial magnetic stimulation for patients suffering from depression and suicidality.
Unlike larger biotech companies, NRX still carries substantial financing and execution risk. This remains a small-cap biotech company operating in a difficult capital environment.
Today's Change
(
-0.77
%) $
-0.03
Current Price
$
3.89
But mental health and neuropsychiatric treatment remain major unmet medical needs, and investors are paying increasing attention to companies targeting severe depression, PTSD, and suicidality. If NRX secures regulatory approval or delivers positive clinical data over the next 12 months, the stock could attract significantly more institutional attention.
Biotech investing is never about certainty. Clinical failures happen. Regulatory setbacks happen. Capital raises happen. But Schrödinger has a real software business supporting its AI platform, Sarepta has nearly $2 billion in annual product revenue despite ongoing controversy, and NRX has multiple regulatory catalysts approaching within the next several quarters.
That's why these are my top three biotech stocks for May 2026.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alliance Wealth Advisors LLC boosted its stake in shares of Community Financial System, Inc. (NYSE: CBU) by 95.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,825 shares of the bank's stock after purchasing an additional 10,150 shares during the period. Alliance Wealth
SG Americas Securities LLC raised its stake in Community Financial System, Inc. (NYSE:CBU – Free Report) by 2,430.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 168,892 shares of the bank’s stock after buying an additional 162,218 shares during the quarter. SG Americas Securities LLC owned 0.32% of Community Financial System worth $9,701,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Community Financial System by 177.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 781 shares of the bank’s stock valued at $44,000 after buying an additional 499 shares during the period. CWM LLC increased its stake in shares of Community Financial System by 56.1% in the third quarter. CWM LLC now owns 899 shares of the bank’s stock worth $53,000 after acquiring an additional 323 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Community Financial System by 14.9% in the third quarter. Smartleaf Asset Management LLC now owns 1,456 shares of the bank’s stock worth $86,000 after acquiring an additional 189 shares during the last quarter. Covestor Ltd raised its holdings in shares of Community Financial System by 110.7% during the third quarter. Covestor Ltd now owns 1,479 shares of the bank’s stock worth $87,000 after acquiring an additional 777 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Community Financial System during the first quarter valued at $102,000. Hedge funds and other institutional investors own 73.79% of the company’s stock.
Wall Street Analyst Weigh In A number of research analysts have commented on the company. Janney Montgomery Scott downgraded Community Financial System from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 13th. Wall Street Zen raised Community Financial System from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings cut Community Financial System from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, March 23rd. Piper Sandler initiated coverage on Community Financial System in a report on Wednesday, December 3rd. They issued a “neutral” rating and a $62.00 price objective on the stock. Finally, DA Davidson began coverage on shares of Community Financial System in a research report on Wednesday, February 25th. They set a “neutral” rating and a $72.00 price objective on the stock. Five research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $66.67.
Read Our Latest Analysis on CBU
Insider Activity In other Community Financial System news, Director Eric Stickels sold 2,000 shares of Community Financial System stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $64.75, for a total value of $129,500.00. Following the transaction, the director directly owned 33,342 shares of the company’s stock, valued at $2,158,894.50. The trade was a 5.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John F. Whipple sold 4,246 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $65.17, for a total value of $276,711.82. Following the transaction, the director owned 8,506 shares of the company’s stock, valued at approximately $554,336.02. This trade represents a 33.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.01% of the stock is currently owned by insiders.
Community Financial System Price Performance NYSE CBU opened at $56.79 on Monday. Community Financial System, Inc. has a 1 year low of $49.44 and a 1 year high of $67.50. The company has a fifty day simple moving average of $61.58 and a 200 day simple moving average of $59.41. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of 0.23. The company has a market cap of $2.99 billion, a P/E ratio of 14.31 and a beta of 0.80.
Community Financial System (NYSE:CBU – Get Free Report) last announced its earnings results on Tuesday, January 27th. The bank reported $1.12 EPS for the quarter, missing the consensus estimate of $1.13 by ($0.01). The firm had revenue of $215.56 million during the quarter, compared to the consensus estimate of $212.85 million. Community Financial System had a return on equity of 11.09% and a net margin of 20.82%.The business’s revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.94 EPS. On average, sell-side analysts predict that Community Financial System, Inc. will post 4.18 EPS for the current year.
Community Financial System Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 10th. Investors of record on Monday, March 16th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Monday, March 16th. Community Financial System’s payout ratio is currently 47.36%.
Community Financial System Company Profile (Free Report)
Community Financial System (NYSE: CBU) is the bank holding company for Community Bank, National Association, a full-service commercial bank headquartered in DeWitt, New York. Through its principal subsidiary, the company offers a range of banking and financial services designed to meet the needs of both consumer and business clients. Its organizational structure centers on community-based banking operations supported by centralized technology, risk management and administrative functions.
The company’s product offerings include deposit accounts, residential and commercial mortgage loans, commercial and consumer lending, treasury and cash management services, and electronic banking.
See Also Five stocks we like better than Community Financial System
Receive News & Ratings for Community Financial System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Community Financial System and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESG Americas Securities LLC Has $9.51 Million Stock Holdings in Dover Corporation $DOV
NEXT HEADLINE »SG Americas Securities LLC Boosts Stock Holdings in Kinsale Capital Group, Inc. $KNSL
SYRACUSE, N.Y.--(BUSINESS WIRE)--Community Financial System, Inc. (NYSE: CBU) (the “Company”) announced that it has declared a quarterly cash dividend of $0.47 per share on its common stock. The dividend will be payable on July 10, 2026 to shareholders of record as of June 15, 2026. The $0.47 cash dividend represents an annualized yield of 3.0% based on the closing share price of $62.70 on April 21, 2026.
About Community Financial System, Inc.
Community Financial System, Inc. is a diversified financial services company that is focused on four main business lines – banking services, employee benefit services, insurance services and wealth management services. Its banking subsidiary, Community Bank, N.A., is among the country’s 100 largest banking institutions with over $17 billion in assets and operates approximately 200 customer facilities across Upstate New York, Northeastern Pennsylvania, Vermont, Western Massachusetts and Southern New Hampshire. The Company’s Benefit Plans Administrative Services, Inc. subsidiary is a leading provider of employee benefits administration, trust services, collective investment fund administration, and actuarial consulting services to customers on a national scale. The Company’s OneGroup NY, Inc. subsidiary is a top 68 U.S. insurance agency. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Nottingham Financial Group operating unit. The Company is listed on the New York Stock Exchange and the Company’s stock trades under the symbol CBU. For more information about the Company and each of its four main business lines visit https://communityfinancialsystem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of CBU’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The following factors, among others, could cause the actual results of CBU’s operations to differ materially from its expectations: the macroeconomic and other challenges and uncertainties related to or resulting from current and future economic and market conditions, including the effects on CRE and housing or vehicle prices, unemployment rates, high inflation, U.S. fiscal debt, budget and tax matters, geopolitical matters, tariffs and global economic growth; fiscal and monetary policies of the Federal Reserve Board; the potential adverse effects of unusual and infrequently occurring events; litigation and actions of regulatory authorities; management’s estimates and projections of interest rates and interest rate policies; the effect of changes in the level of checking, savings, or money market account deposit balances and other factors that affect net interest margin; future provisions for credit losses on loans and debt securities; changes in nonperforming assets; ability to contain costs in inflationary conditions; the effect on financial market valuations on CBU’s fee income businesses, including its employee benefit services, wealth management services, and insurance services businesses; the successful integration of operations of its acquisitions and performance of new branches; competition; changes in legislation or regulatory requirements, including capital requirements; and the timing for receiving regulatory approvals and completing merger and acquisition transactions. For more information about factors that could cause actual results to differ materially from CBU’s expectations, refer to its annual, periodic and other reports filed with the Securities and Exchange Commission (“SEC”), including the discussion under the “Risk Factors” section of such reports filed with the SEC and available on CBU’s website at https://communityfinancialsystem.com and on the SEC’s website at https://sec.gov. Further, any forward-looking statement speaks only as of the date on which it is made, and CBU undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.
For the quarter ended March 2026, Community Financial System (CBU - Free Report) reported revenue of $214.14 million, up 8.6% over the same period last year. EPS came in at $1.09, compared to $0.93 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $217.27 million, representing a surprise of -1.44%. The company delivered an EPS surprise of -0.73%, with the consensus EPS estimate being $1.10.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Community Financial performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Efficiency ratio (GAAP): 62.4% versus the four-analyst average estimate of 62.4%.Net Interest Margin: 3.4% versus 3.5% estimated by four analysts on average.Average Balances - Total interest-earning assets: $15.94 billion versus $15.93 billion estimated by four analysts on average.Net charge-offs/average loans: 0.1% versus the three-analyst average estimate of 0.1%.Total Non-Interest Income: $78.57 million compared to the $81.62 million average estimate based on four analysts.Mortgage banking: $1.1 million compared to the $0.62 million average estimate based on three analysts.Fully tax-equivalent net interest income: $135.56 million versus $135.63 million estimated by three analysts on average.Deposit service and other banking fees: $20.71 million versus $21.31 million estimated by three analysts on average.Wealth management services: $10.33 million compared to the $9.89 million average estimate based on two analysts.Insurance services: $12.59 million versus $15.05 million estimated by two analysts on average.Employee benefit services: $34.57 million versus the two-analyst average estimate of $35.16 million.Net Interest Income: $134.71 million compared to the $135.01 million average estimate based on two analysts.View all Key Company Metrics for Community Financial here>>>
Shares of Community Financial have returned +7.7% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Community Financial (CBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
First Horizon delivered solid Q1 results, with EPS of $0.53 and a 15% return on tangible equity, beating expectations. FHN maintains strong credit quality, stable non-interest-bearing deposits, and prudent capital returns, including a 7% share count reduction via buybacks. Loan growth is steady, with limited CRE exposure; NDFI risk is mitigated by low-risk, short-term mortgage warehousing.
, /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") is pleased to announce the addition of two new associates and the promotion of a current team member, further strengthening its banking capabilities in the Acadiana market.
Eddie Buttross has been promoted to Commercial Banking Group Manager. A respected leader within First Horizon, Buttross will oversee commercial banking efforts in the market, continuing to strengthen client relationships while leading a growing team of bankers.
Eddie Buttross, First Horizon Bank
Christine Kieu, First Horizon Bank
Melinda Brahan, First Horizon Bank Christine Kieu has joined First Horizon Bank as Senior Private Client Relationship Manager. With 25 years of banking experience, Kieu brings a client-first approach and a proven track record of delivering strategic financial solutions.
Melinda Brahan joins the team as Treasury Management Sales Officer. In this role, she partners with commercial clients to deliver tailored cash management and treasury solutions that support business operations and long-term growth.
"These announcements reflect the momentum we're seeing across our Acadiana Market," said Jerry Prejean, Acadiana Market President for First Horizon Bank. "Eddie, Christine and Melinda bring specialized expertise and a shared commitment to serving clients, further strengthening how we support businesses and individuals across the region."
These associates will all be based in First Horizon Bank's downtown Lafayette office.
About First Horizon
First Horizon Corp. (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
, /PRNewswire/ -- First Horizon Corporation (NYSE: FHN or the "Company") today announced that its board of directors declared a quarterly cash dividend of $0.17 per share on FHN's common stock. The dividend is payable on July 1, 2026, to shareholders of record at the close of business on June 12, 2026.
Preferred Dividend Information
Cash dividends were also declared on the Company's Series E, Series F and Series H Preferred Stock, and on First Horizon Bank's Class A Non-Cumulative Perpetual Preferred Stock, as follows:
FHN Series E
Quarterly cash dividend of $1,625.00 per share on FHN's 6.50% Non-Cumulative Perpetual Preferred Stock, Series E ("Series E Preferred Stock"). This equates to a cash dividend of $0.40625 per Depositary Share (NYSE: FHN PRE), each of which represents a 1/4,000th interest in a share of the Series E Preferred Stock. The dividend is payable on July 10, 2026, to shareholders of record at the close of business on June 25, 2026.
FHN Series F
Quarterly cash dividend of $1,175.00 per share on FHN's 4.70% Non-Cumulative Perpetual Preferred Stock, Series F ("Series F Preferred Stock"). This equates to a cash dividend of $0.29375 per Depositary Share (NYSE: FHN PRF), each of which represents a 1/4,000th interest in a share of the Series F Preferred Stock. The dividend is payable on July 10, 2026, to shareholders of record at the close of business on June 25, 2026.
FHN Series H
Quarterly cash dividend of $2,212.50 per share on FHN's 6.75% Non-Cumulative Perpetual Preferred Stock, Series H ("Series H Preferred Stock"). This equates to a cash dividend of $0.553125 per Depositary Share (NYSE: FHN PRH), each of which represents a 1/4,000th interest in a share of the Series H Preferred Stock. The dividend is payable on July 10, 2026, to shareholders of record at the close of business on June 25, 2026.
First Horizon Bank Class A
Quarterly cash dividend of $12.10843 per share on First Horizon Bank's Class A Non-Cumulative Perpetual Preferred Stock. The dividend is payable on July 10, 2026, to shareholders of record at the close of business on June 25, 2026.
About First Horizon
First Horizon Corporation (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
MEMPHIS, Tenn. , May 4, 2026 /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") announced today James Gifas has joined the organization as Senior Vice President, Deputy Head of Treasury Management.
MEMPHIS, Tenn., May 11, 2026 /PRNewswire/ -- First Horizon Corporation (NYSE: FHN or "First Horizon") is proud to announce that Tyler Craft, Senior Vice President and Head of Investor Relations, has been named to the Triangle Business Journal 2026 40 Under 40 list.
, /PRNewswire/ -- First Horizon Bank (NYSE: FHN) is pleased to announce that Wanda Weinberger has joined the company as Banking Center Manager of its Pan American Life location at 601 Poydras Street in New Orleans.
In her role, Weinberger will oversee the daily operations and client experience at the Pan American Life location while leading a team focused on relationship-driven banking and personalized financial solutions for clients throughout the Greater New Orleans area.
Wanda Weinberger - First Horizon Banking Center Manager Weinberger has more than 35 years of banking and financial services experience, with an extensive background in consumer lending, mortgage lending, branch management, operations and client relationship management. Throughout her career, she has held leadership positions with several financial institutions including Frost Bank, JPMorgan Chase, Wells Fargo, Texans Credit Union and ASI Federal Credit Union.
"We are excited to welcome Wanda to First Horizon Bank," said Jimmy Dunn, New Orleans Market President for First Horizon Bank. "Her leadership experience, client-first mindset and dedication to building relationships make her an outstanding addition to our New Orleans banking team."
About First Horizon
First Horizon Corp. (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
MEMPHIS, Tenn., May 14, 2026 /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") is pleased to announce it served nearly 8,700 students through the 2026 American Bankers Association (ABA) Foundation's Teach Children to Save financial education movement.
MEMPHIS, Tenn., May 14, 2026 /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") today announced it has earned a spot on the VETS Indexes Employer Awards list.
A month has gone by since the last earnings report for First Horizon National (FHN - Free Report) . Shares have lost about 1.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is First Horizon due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for First Horizon Corporation before we dive into how investors and analysts have reacted as of late.
First Horizon Q1 Earnings Beat Estimates on Higher NII & Fee IncomeFirst Horizon posted first-quarter 2026 earnings per share of 53 cents, surpassing the Zacks Consensus Estimate of 49 cents. This compares favorably with 42 cents in the year-ago quarter.
Results benefited from higher net interest income (NII) and a rise in non-interest income, along with improved credit quality. However, the rise in expenses remains a headwind.
Net income available to its common shareholders was $257 million, up 21% year over year.
Revenues & Expenses Rise
Total quarterly revenues were $862 million, which increased 6% year over year. The top line missed the Zacks Consensus Estimate of $866 million.
NII increased 6% year over year to $667 million. Additionally, the net interest margin expanded 10 basis points from the prior-year quarter to 3.52%.
Non-interest income was $195 million, rising 7% year over year. Growth was driven by higher service charges and fees, mortgage banking revenues, brokerage, trust and insurance income, and fixed income revenues.
Non-interest expenses increased 4% year over year to $505 million. The rise was mainly due to higher salaries and benefits, occupancy and equipment costs, and outside services expenses.
The efficiency ratio was 58.54%, down from 60.06% in the same quarter last year. A decline in the efficiency ratio indicates improved profitability.
Loans & Deposits Balances Increase
Average loans and leases were $63.2 billion, rising 3% year over year.
Average deposits were $66.2 billion, which increased 3% year over year.
Credit Quality: Mixed Bag
Non-performing loans and leases totaled roughly $606 million, slightly lower than the prior-year quarter.
The allowance for credit losses to loans and leases ratio was 1.28%, down from 1.45% in the year-ago quarter.
Net charge-offs were $29 million, relatively stable year over year. Provision for credit losses was $15 million compared with $40 million in the year-ago quarter.
Capital Ratios Deteriorate
The common equity tier 1 (CET1) ratio was 10.5%, down from 10.9% in the year-ago quarter.
The total capital ratio was 13.7%, down from 14.1% a year ago. The tier 1 leverage ratio improved slightly to 10.6% from 10.5% in the prior-year quarter.
Notably, the company repurchased $233 million worth of shares during the quarter.
2026 OutlookAdjusted revenues are expected to rise 3-7% from the $3.42 billion reported in 2025.
Adjusted non-interest expenses are expected to remain flat compared with the $2.05 billion reported in 2024.
The net charge-off ratio is anticipated to be 0.15-0.25% bps compared with the 2025 reported figure of 0.19%, reflecting continued strong credit performance.
The CET1 ratio is now expected to remain around the 10.5% level, compared with its prior expectation of a 10.5–10.75% range.
The effective tax rate is forecast to be 21-23%.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a flat trend in estimates review.
VGM ScoresCurrently, First Horizon has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. However, the stock has a grade of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook First Horizon has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
, /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") and First Horizon Coliseum are proud to announce a bold new shareable fan experience and photo opportunity designed to capture the excitement of Coliseum guests attending live events at the storied regional venue.
First Horizon Coliseum - Greensboro, NC A custom-built, 10-foot-long replica event ticket display will be installed this week, at the main entrance ramp on the south end of the Coliseum. Designed to resemble a classic admission ticket, the oversized event ticket features a lighted marquee-style center panel with interchangeable lettering that will highlight Coliseum events.
"By sponsoring this experience, First Horizon is playing a role in creating connections that make this dynamic region a vibrant place to live and work," said Laura Bunn, Executive Vice President and Mid-Atlantic Regional President for First Horizon. "Our investment in the Coliseum reflects our commitment to the community by supporting local venues that bring people together."
The front of the illuminated sign features the "Memories on the Horizon" tagline and the reverse side, visible after exiting the Coliseum, includes "Thank You for Visiting!" and "Come back and make more memories with us," messages, encouraging guests to snap a final photo on their way out. Its placement ensures high visibility for guests attending the venue's wide variety of live events.
"This installation is a bold, fun reminder of what makes the Triad and the Coliseum so special to our region," said Todd Williams, Triad Market President for First Horizon Bank. "First Horizon is proud to be part of so many memorable experiences that bring our community together and enrich the lives of the people who live here."
"This addition not only enhances our main entrance but creates a natural gathering point for guests," said Scott Johnson, General Manager of the Coliseum for Oak View Group. "People want to document experiences in a way that feels unique. This display gives them a built-in moment to celebrate—whether it's their first concert, a big game or a graduation."
The display was designed by Greensboro Complex graphic designer Jack Wilson and fabricated by Signage Industries of Greensboro, N.C.
About First Horizon
First Horizon Corp. (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
, /PRNewswire/ -- First Horizon Corporation (NYSE: FHN) today announced Chief Financial Officer Hope Dmuchowski will participate in the Morgan Stanley U.S. Financials Conference on June 10, 2026, at 8:15 am ET.
A live webcast of the event along with an audio replay will be available via the events and presentations section of the First Horizon Investor Relations website at https://ir.firsthorizon.com/events-and-presentations/default.aspx.
The presentation and any related materials may contain forward-looking statements, including guidance, involving significant risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements, including those factors described in FHN's recent 10-K, 10-Q, 8-K, and other reports and filings with the SEC. FHN disclaims any obligation to update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements to reflect future events or developments.
About First Horizon
First Horizon Corporation (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
, /PRNewswire/ -- First Horizon Corporation (NYSE: FHN or "First Horizon") today announced it has earned the Great Place to Work® Certification, reflecting its ongoing commitment to cultivating a collaborative workplace where associates feel valued, supported and empowered to serve their colleagues, clients and communities.
Each year, U.S. and global companies are recognized as Great Place to Work-Certified based on direct feedback from their employees through an independent survey process measuring trust, respect, fairness, pride and collaboration in the workplace.
First Horizon Earns Great Place to Work Certification "Being named Great Place to Work-Certified for the seventh time is a proud moment for First Horizon," said Tanya Hart, Senior Executive Vice President and Chief Human Resources Officer for First Horizon. "Our associates continue to make this possible by serving one another, our clients and strengthening the communities we share."
About First Horizon
First Horizon Corp. (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
MEMPHIS, Tenn., June 3, 2026 /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") is pleased to announce that Ray Cenolli has joined the First Horizon team as Retail Banking Executive based in Memphis and covering the Retail Mid-South Region of Alabama, Arkansas, Mississippi and Southern Tennessee.
, /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") is pleased to announce that Kevin Piker has joined the organization as Commercial Relationship Manager serving the Acadiana Market.
Piker brings more than 25 years of banking and commercial lending experience to First Horizon Bank. In his new role, he will focus on helping businesses throughout Acadiana achieve their financial goals through customized banking solutions and relationship-driven service.
Kevin Piker, First Horizon Bank Prior to joining First Horizon Bank, Piker held roles with Capital One, JD Bank and JPMorgan Chase, where he built extensive experience in commercial banking and client relationship management.
"Kevin's experience and commitment to building lasting client relationships make him a strong addition to our commercial banking team," said Jerry Prejean, Acadiana Market President for First Horizon Bank. "We are excited to welcome him to First Horizon and look forward to the impact he will make as we continue expanding our team and serving businesses throughout Acadiana."
About First Horizon
First Horizon Corporation (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
, /PRNewswire/ -- First Horizon Bank (NYSE: FHN or "First Horizon") announced today that Christopher Tusa, Assistant Vice President and Business Banking Relationship Manager, has joined the Habitat for Humanity STW Board of Directors.
Tusa has served First Horizon commercial and business banking clients for more than five years and has been in the industry since 2013. He is known for a practical, client-first approach and a commitment to building lasting partnerships across Louisiana's Northshore and the greater New Orleans area.
Chris Tusa - First Horizon Bank "I'm proud to serve on the STW board. As someone who works alongside local business owners every day, I know how stability at home fuels success at work and out in the community," said Chris Tusa. "It's an honor to support Habitat's mission to build strength and stability across New Orleans."
"Christopher brings practical financial acumen and a heart for service. His leadership will help us accelerate innovative collaborations and deliver safe, well-appointed and affordable homes for more families in St. Tammy West," said Terri Gage, Habitat for Humanity STW President and CEO.
About First Horizon
First Horizon Corp. (NYSE: FHN), with $84.1 billion in assets as of March 31, 2026, is a leading regional financial services company, dedicated to helping our clients, communities and associates unlock their full potential with capital and counsel. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates in 12 states concentrated in the southern U.S. The Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, and mortgage banking services. First Horizon has been recognized as one of the nation's best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. Bank. More information is available at www.FirstHorizon.com.
Players in the Zacks Beverages – Alcohol industry remain under pressure as inflation hikes costs across labor, transportation and raw materials. Higher ingredient, packaging and shipping expenses are squeezing margins, while increased spending on marketing, promotions and daily operations continues to weigh on profitability. Tariffs add another layer of risk, pushing up prices for imported brands, dampening demand and disrupting supply chains.
Despite these headwinds, growth opportunities persist. Premiumization continues to gain traction as consumers shift toward higher-quality, distinctive offerings. Segments like ready-to-drink spirits, canned wines and cocktails, hard seltzers, ciders and flavored malt beverages are reshaping the market, attracting younger consumers while offering convenience and variety to more established drinkers.
To capitalize on these trends, leading players, including Anheuser-Busch InBev (BUD - Free Report) , Diageo Plc (DEO - Free Report) , Constellation Brands Inc. (STZ - Free Report) , Brown-Forman Corporation (BF.B - Free Report) and Molson Coors Beverage Company (TAP - Free Report) , are intensifying investments in innovation, technology and premium brand positioning. While volatility in input costs and tariffs may continue to pressure margins in the near term, strong brand equity and premium-led innovation are expected to remain the industry’s primary growth drivers.
About the Industry The Zacks Beverages – Alcohol industry mainly comprises producers, importers, exporters, marketers and sellers of alcoholic beverages like beer, craft beer, ciders, wine, rum, whiskey, liqueurs, vodka, tequila, champagnes, brandy, amaretto, ready-to-drink (RTD) cocktails and malt. Some industry players also produce and sell non-alcoholic beverages like carbonated soft drinks, sparkling waters, bottled water, energy drinks, powdered and natural juices, and RTD teas. The companies sell products through wholesalers and retailers like supermarkets, warehouse clubs, grocery stores, convenience stores, package stores, drug stores and other retail outlets. The industry participants also sell beer directly to consumers in cans and bottles at restaurants, pubs, bars and liquor stores. Some brewers operate brewpubs or tasting rooms at breweries, offering consumers the freshest beer.
What's Shaping the Future of Beverages - Alcohol Industry Elevated Costs: The alcohol industry continues to grapple with elevated cost pressures from inflation across labor, transportation and raw materials. Higher prices for key inputs such as grains and fruits, along with rising costs for packaging, co-packing, fuel and logistics, have pushed up production and operating expenses, weighing on the gross and operating margins.
In addition to input inflation, companies are facing increased spending on advertising, promotions and SG&A as they step up brand investments, media activity and local market execution. Higher freight costs tied to volume growth, along with rising wages and discretionary expenses, are contributing to margin pressure and SG&A deleverage. Many industry participants expect these headwinds to persist in the near term, continuing to challenge profitability.
Potential Tariff Impacts: Tariffs imposed by President Donald Trump are expected to create severe headwinds for the U.S. beverage alcohol industry, with implications for pricing, supply chains, trade flows and consumer demand. Tariffs on imports from Canada, Mexico and China raise input and landed costs for a range of imported spirits and beers, including well-known international brands. These higher costs are likely to be passed on to consumers, resulting in price increases that could weigh on volumes. At the same time, supply chains may face disruption as companies reassess sourcing and logistics, potentially leading to delays, tighter availability and higher operating expenses. As prices rise and choice narrows, consumers may trade down or reduce consumption, pressuring industry sales and margins.
Premiumization & Product Diversification: Premiumization remains a core growth engine for the alcohol industry as consumers increasingly gravitate toward distinctive flavors, higher-quality offerings and experiential brands. In response, beverage companies are broadening their portfolios to capture demand for premium and super-premium products while extending beyond traditional beer, wine and spirits. The category mix is rapidly evolving, with strong momentum in craft spirits, low- and no-alcohol offerings, RTD spirits, canned wines and cocktails, hard seltzers, cider and flavored malt beverages. As consumer preferences fragment and occasions diversify, sustained innovation and agile product development have become critical for brands seeking to remain relevant, defend pricing power and drive long-term growth.
Zacks Industry Rank Indicates Dull Prospects The Zacks Beverages – Alcohol industry is a 14-stock group within the broader Zacks Consumer Staples sector. The industry currently carries a Zacks Industry Rank #205, placing it at the bottom 16% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates dull near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
The industry’s positioning in the bottom 50% of the Zacks-ranked industries is a result of a negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gradually losing confidence in this group’s earnings growth potential.
Before we present a few stocks that you may want to consider for your portfolio, let us take a look at the industry’s recent stock-market performance and valuation picture.
Industry Underperforms S&P 500 The Zacks Beverages – Alcohol industry has outperformed the broader sector and underperformed the S&P 500 in the past year.
The stocks in the industry have collectively returned 4.8% in the past year, whereas the Zacks Consumer Staples sector has declined 3.2%. Meanwhile, the Zacks S&P 500 composite has rallied 34.6%.
1-Year Price Performance
Beverages - Alcohol Industry's Valuation Based on the forward 12-month price-to-earnings (P/E) ratio, commonly used to value Consumer Staples stocks, the industry is currently trading at 15.71X compared with the S&P 500’s 21.49X and the sector’s 16.57X.
Over the last five years, the industry traded as high as 26.77X, as low as 13.77X and at the median of 18.61X, as the chart below shows.
Price-to-Earnings Ratio (Past 5 Years)
5 Alcohol Beverages Stocks to Keep a Close Eye on None of the stocks in the Zacks Beverages – Alcohol space currently sports a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy). However, we have selected five stocks with a Zacks Rank #3 (Hold) to watch from the same industry. You can see the complete list of today’s Zacks #1 Rank stocks here.
Let us have a look at the companies.
Anheuser-Busch InBev: Also known as AB InBev, this is a global brewing leader with a portfolio of iconic brands spanning diverse geographies. Its leading positions across key markets and expansive global footprint provide meaningful scale advantages, enabling efficient operations and the ability to grow multi-country brands worldwide. The company continues to benefit from resilient consumer demand for its core brands, supported by strong business momentum, driven by disciplined execution, sustained brand investment and an accelerated digital transformation agenda. Premiumization remains a central growth lever, as consumers increasingly trade up within the beer category.
Beyond core beer, AB InBev is steadily expanding its Beyond Beer portfolio, encompassing ready-to-drink offerings, such as canned wines and cocktails, along with hard seltzers, ciders and flavored malt beverages. This diversification strategy is enhancing relevance across occasions and consumer segments, while providing an incremental growth runway and supporting top-line momentum. The Zacks Consensus Estimate for AB InBev’s 2027 sales and earnings suggests growth of 6.7% and 12.3% from the year-ago period’s reported figures. The consensus mark for the company’s 2027 earnings has moved down 0.5% in the past seven days. The Zacks Rank #3 stock has gained 16.9% in the past year.
Price & Consensus: BUD
Diageo: The stock of this London-based leading beverage company has declined 25.6% in the past year. DEO operates in approximately 180 countries, and is involved in producing, distilling, brewing, bottling, packaging, and distributing spirits, wine and beer. The company continues to place innovation and consumer moderation at the center of its long-term growth strategy, addressing evolving consumption patterns and diversifying its portfolio. Innovation remains a key driver, with strong momentum across tequila, whisky, beer and RTD formats.
Equally important is Diageo’s push into moderation, wherein it has established clear leadership in non-alcoholic spirits. The company is refining its $2-billion productivity program to drive efficiency across the business while ensuring long-term sustainable growth. A key focus is balancing cost savings with strategic reinvestment, particularly in marketing and brand activation. The Zacks Consensus Estimate for Diageo’s fiscal 2027 EPS has been unchanged in the past 30 days. The consensus estimate for fiscal 2027 earnings suggests a decline of 3.2% from the year-ago period’s reported figure.
Price & Consensus: DEO
Constellation Brands: The Victor, NY-based third-largest beer company and a leading, high-end wine company in the United States continues to benefit from a sharp focus on brand building and a steady cadence of innovation. The company’s premiumization strategy remains a key growth driver, led by the sustained strength of the Modelo and Corona brand families and continued traction across its Power Brands portfolio. Its beer business is benefiting from premium and above-premium trends, supported by growth in traditional beer and adjacent categories, such as flavored beer, seltzers, RTD spirits and flavored malt beverages.
STZ is actively investing to extend the momentum of its Power Brands, aligning innovation with evolving consumer preferences and delivering successful product launches. Meanwhile, the company’s digital momentum continues to build through platforms, such as Instacart, Drizly and retailer-owned channels, reflecting consumers’ growing preference for convenience-driven purchasing. The Zacks Consensus Estimate for STZ’s fiscal 2027 earnings per share has moved down 3.5% in the past seven days. The consensus estimate for fiscal 2027 sales and earnings suggests growth of 0.6% and 0.9%, respectively, from the year-ago period’s reported figures. The Zacks Rank #3 stock has lost 10.2% in the past year.
Price & Consensus: STZ
Brown-Forman: Based in Louisville, KY, this is a global spirits company that manufactures, distills, bottles, imports, exports, markets and sells a broad portfolio of premium alcoholic beverages. The company’s growth strategy is anchored in premiumization, with a clear focus on high-quality, premium and super-premium spirits that support brand equity and margin resilience. The portfolio has been streamlined around core power brands such as Jack Daniel’s and Woodford Reserve, complemented by successful additions like the Jack Daniel’s and Coca-Cola RTD and the integration of super-premium labels Gin Mare and Diplomático.
Emerging markets continue to provide a strong growth offset, driven by rising middle-class demand and momentum across the Jack Daniel’s family. Disciplined pricing, innovation, distribution evolution and tighter cost control underpin long-term value creation despite near-term pressures. The Zacks Consensus Estimate for BF.B’s fiscal 2026 sales and earnings suggests declines of 2.3% and 4.4%, respectively, from the year-ago period’s reported figures. The consensus mark for the Zacks Rank #3 company’s fiscal 2026 earnings has moved up 1.7% in the past 30 days. BF.B has declined 11.6% in the past year.
Price & Consensus: BF.B
Molson Coors: The stock of this Chicago, IL-based leading beverage company has declined 25.6% in the past year. TAP is on track with its revitalization plan, focused on achieving sustainable top-line growth by streamlining its organization and reinvesting resources into its brands and capabilities. Investments, partnerships and product launches, which are part of its revitalization plan, have been aiding the company.
Molson Coors has been committed to increasing its market share through innovation and premiumization. Intending to accelerate portfolio premiumization, TAP has been aggressively growing its above-premium portfolio in the past few years. The Zacks Consensus Estimate for Molson Coors’ 2026 EPS has been unchanged in the past 30 days. The consensus estimate for the Zacks Rank #3 company’s 2026 sales and earnings suggests declines of 0.2% and 11.8%, respectively, from the year-ago period’s reported figures.
Price & Consensus: TAP
Zacks' 7 Best Strong Buy Stocks (New Research Report) Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Bayforest Capital Ltd cut its position in Constellation Brands Inc (NYSE:STZ – Free Report) by 53.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,234 shares of the company’s stock after selling 3,740 shares during the quarter. Bayforest Capital Ltd’s holdings in Constellation Brands were worth $446,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Constellation Brands by 3.3% in the third quarter. Vanguard Group Inc. now owns 18,202,611 shares of the company’s stock valued at $2,451,346,000 after purchasing an additional 573,766 shares during the last quarter. Capital International Investors raised its position in Constellation Brands by 0.7% in the third quarter. Capital International Investors now owns 4,337,054 shares of the company’s stock valued at $584,135,000 after purchasing an additional 28,036 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its position in Constellation Brands by 1.0% in the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 3,710,940 shares of the company’s stock valued at $499,752,000 after purchasing an additional 35,085 shares during the last quarter. Ameriprise Financial Inc. raised its position in Constellation Brands by 76.7% in the third quarter. Ameriprise Financial Inc. now owns 3,126,644 shares of the company’s stock valued at $421,059,000 after purchasing an additional 1,356,903 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in Constellation Brands by 15.5% in the third quarter. Van ECK Associates Corp now owns 2,160,202 shares of the company’s stock valued at $290,915,000 after purchasing an additional 290,701 shares during the last quarter. 77.34% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets Several equities analysts have commented on STZ shares. Deutsche Bank Aktiengesellschaft increased their target price on Constellation Brands from $154.00 to $155.00 and gave the company a “hold” rating in a research report on Friday, April 10th. Wells Fargo & Company raised their price objective on Constellation Brands from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Sanford C. Bernstein raised their price objective on Constellation Brands from $195.00 to $197.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Weiss Ratings upgraded Constellation Brands from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Finally, Evercore set a $175.00 price objective on Constellation Brands and gave the stock an “outperform” rating in a research report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Constellation Brands has an average rating of “Moderate Buy” and a consensus target price of $178.14.
Check Out Our Latest Stock Analysis on STZ
Constellation Brands Price Performance Shares of STZ opened at $162.11 on Friday. Constellation Brands Inc has a 1 year low of $126.45 and a 1 year high of $196.91. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.08 and a quick ratio of 0.55. The company has a market capitalization of $28.11 billion, a price-to-earnings ratio of 16.90, a price-to-earnings-growth ratio of 3.59 and a beta of 1.75. The business has a 50-day moving average of $154.87 and a 200-day moving average of $146.75.
Constellation Brands (NYSE:STZ – Get Free Report) last issued its quarterly earnings data on Wednesday, April 8th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.71 by $0.19. Constellation Brands had a return on equity of 26.18% and a net margin of 17.29%.The company had revenue of $1.92 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same period last year, the company earned $2.63 earnings per share. The firm’s revenue was down 11.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Constellation Brands Inc will post 13.5 earnings per share for the current year.
Constellation Brands Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 14th. Investors of record on Wednesday, April 29th will be paid a dividend of $1.03 per share. This is an increase from Constellation Brands’s previous quarterly dividend of $1.02. This represents a $4.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 29th. Constellation Brands’s payout ratio is 42.96%.
Constellation Brands Profile (Free Report)
Constellation Brands, Inc is a leading producer and marketer of beer, wine and spirits, with operations spanning production, importation, marketing and distribution. The company’s beverage portfolio includes a range of premium and mainstream wines and spirits alongside major imported beer brands; in the U.S. market Constellation is widely known for its role in bringing Mexican imports such as Corona and Modelo to American consumers. Constellation supplies retail, on‑premise and foodservice channels and supports its brands with national sales and marketing platforms and supply‑chain capabilities.
The company traces its roots to the Canandaigua Wine Company, founded by Marvin Sands in 1945, and evolved through organic growth and acquisition into a diversified beverage company.
See Also Five stocks we like better than Constellation Brands
Receive News & Ratings for Constellation Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Brands and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBayforest Capital Ltd Sells 4,916 Shares of Cirrus Logic, Inc. $CRUS
NEXT HEADLINE »Bayforest Capital Ltd Sells 20,197 Shares of SolarEdge Technologies, Inc. $SEDG
